The role of cell penetrating peptides (CPPs) has been challenged in recent years for drug delivery to ocular tissues for the targeting of both anterior and posterior segments. The enhancement of trans-corneal transport for anterior segment targeting is a very important issue possibly leading to important outcomes on efficacy and to the opportunity of topical administration of molecules with unfavorable penetration properties. The aim of the present work was the design and synthesis of new CPPs, deriving from the structure of PEP-1 peptide. Synthesized peptides were labeled with 5-carboxyfluorescein (5-FAM), and their diffusion behavior and distribution inside the cornea were evaluated by a validated ex vivo model and a confocal microscopy approach. Newly synthesized peptides showed similar corneal permeation profiles as PEP-1 (Papp = 0.75 ± 0.56 × 10-6 cm/s), about 2.6-fold higher than 5-FAM (Papp = 0.29 ± 0.08 × 10-6 cm/s) despite the higher molecular weight. Confocal microscopy experiments highlighted the tendency of PEP-1 and its derived peptides to localize in the intercellular space and/or in the plasma membrane. Noteworthy, using penetratin as positive control, a higher trans-corneal permeation (Papp = 6.18 ± 1.46 × 10-6 cm/s) was evidenced together with a diffusion by intracellular route and a different accumulation between wings and basal epithelial cells, probably depending on the stage of cell development. Finally, PEP-1 and pep-7 proved to be safe and well tolerated when tested on human conjuctival cell line.

Design and synthesis of new cell penetrating peptides: Diffusion and distribution inside the cornea / Pescina, Silvia; Sala, Marina; Padula, Cristina; Scala, Maria Carmina; Spensiero, Antonia; Belletti, Silvana; Gatti, Rita; Novellino, Ettore; Campiglia, Pietro; Santi, Patrizia; Nicoli, Sara; Ostacolo, Carmine. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 13:11(2016), pp. 3876-3883. [10.1021/acs.molpharmaceut.6b00658]

Design and synthesis of new cell penetrating peptides: Diffusion and distribution inside the cornea

PESCINA, Silvia;PADULA, Cristina;BELLETTI, Silvana;GATTI, Rita;NOVELLINO, ETTORE;SANTI, Patrizia;NICOLI, Sara;
2016

Abstract

The role of cell penetrating peptides (CPPs) has been challenged in recent years for drug delivery to ocular tissues for the targeting of both anterior and posterior segments. The enhancement of trans-corneal transport for anterior segment targeting is a very important issue possibly leading to important outcomes on efficacy and to the opportunity of topical administration of molecules with unfavorable penetration properties. The aim of the present work was the design and synthesis of new CPPs, deriving from the structure of PEP-1 peptide. Synthesized peptides were labeled with 5-carboxyfluorescein (5-FAM), and their diffusion behavior and distribution inside the cornea were evaluated by a validated ex vivo model and a confocal microscopy approach. Newly synthesized peptides showed similar corneal permeation profiles as PEP-1 (Papp = 0.75 ± 0.56 × 10-6 cm/s), about 2.6-fold higher than 5-FAM (Papp = 0.29 ± 0.08 × 10-6 cm/s) despite the higher molecular weight. Confocal microscopy experiments highlighted the tendency of PEP-1 and its derived peptides to localize in the intercellular space and/or in the plasma membrane. Noteworthy, using penetratin as positive control, a higher trans-corneal permeation (Papp = 6.18 ± 1.46 × 10-6 cm/s) was evidenced together with a diffusion by intracellular route and a different accumulation between wings and basal epithelial cells, probably depending on the stage of cell development. Finally, PEP-1 and pep-7 proved to be safe and well tolerated when tested on human conjuctival cell line.
Design and synthesis of new cell penetrating peptides: Diffusion and distribution inside the cornea / Pescina, Silvia; Sala, Marina; Padula, Cristina; Scala, Maria Carmina; Spensiero, Antonia; Belletti, Silvana; Gatti, Rita; Novellino, Ettore; Campiglia, Pietro; Santi, Patrizia; Nicoli, Sara; Ostacolo, Carmine. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 13:11(2016), pp. 3876-3883. [10.1021/acs.molpharmaceut.6b00658]
File in questo prodotto:
File Dimensione Formato  
CPP 2016-07-15 last (1).pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2818831
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact